Bank of Montreal Can Has $109.18 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of Montreal Can cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 153,267 shares of the biopharmaceutical company's stock after selling 34,890 shares during the quarter. Bank of Montreal Can owned approximately 0.14% of Regeneron Pharmaceuticals worth $109,177,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Pamalican Asset Management Ltd purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $4,915,000. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $356,000. Principal Financial Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its position in Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after buying an additional 4,457 shares during the period. Finally, Fagan Associates Inc. lifted its stake in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $10.12 during trading hours on Monday, reaching $564.30. 274,771 shares of the company's stock were exchanged, compared to its average volume of 706,149. The business has a fifty day moving average price of $659.94 and a 200-day moving average price of $753.23. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $61.69 billion, a P/E ratio of 14.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.